

Blood and Infection
Specialised Immunology and Allergy Services
Specialised Immunology (All Ages)

B09/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
IVIG05a	Proportion of patients with infusions recorded on the national database within 90 days of treatment taking place / product being issued	Of those patients in the denominator, the number with infusions recorded on the national database within 90 days of treatment taking place / product being issued	The total number of active patients registered on the national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
IVIG06b	Proportion of patients receiving immunoglobulin for not routinely commissioned indications whose outcomes are entered on the national database	The total number of patients receiving immunoglobulin for not routinely commissioned indications whose outcomes are entered on the national database. Exclude private patients.	The total number of patients receiving immunoglobulin for not routinely commissioned indications in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
IVIG07	Proportion of long-term patients who have a documented dose review	Of those in the denominator, the number who have a documented dose review	The total number of long-term patients treated in reporting period	Quarter	Quarterly	MDSAS	MDSAS		Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
IVIG11a	Proportion of patients receiving immunoglobulin for designated short-term red / blue indication whose outcomes are entered on the national database	Of those patients in the denominator, the number whose outcomes are entered on the national database	The total number of patients receiving immunoglobulin for designated short-term red / blue indications in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Short-term red / blue indication diagnosis only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
IVIG12a	Proportion of not routinely commissioned patients who have been reviewed and approved by a sub-regional immunoglobulin assessment panel (SRIAP), and who are documented on the national database before commencing immunoglobulin therapy	Of those patients in the denominator, the number who have been reviewed and approved by a sub-regional immunoglobulin assessment panel (SRIAP), and who is documented on the national database before commencing immunoglobulin therapy is commenced	The total number of patients commencing immunoglobulin treatment for not routinely commissioned indications in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
IVIG13	Proportion of long-term neurology patients who have objective measures of improvement documented	Of those patients in the denominator, the number who have objective measures of improvement documented	The total number of long-term Neurology patients treated in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Neurology patients only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
IVIG15a	Proportion of long-term patients who receive an 'annual review' or an 'on going review'	Of those patients in the denominator, the number who receive an 'annual review' or an 'on going review'	The total number of eligible long-term patients registered with infusions who are recorded on the national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Include only patients who have been treated for at least 365 days Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
PID01	Proportion of patients with immunoglobulin trough levels recorded and documented on the national database	Of those patients in the denominator, the number of patients who have immunoglobulin trough levels recorded and documented on the national database	The total number of long-term immunology patients registered on the national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
PID03	Proportion of long-term immunology patients who are on homecare	Of those patients in the denominator, the number of patients on homecare	The total number of long-term immunology patients registered on the national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
PID04	Proportion of patients on homecare who have received training from an accredited home therapy centre	Of those patients in denominator, the number of patients who received training after accreditation of the home therapy centre	The total number of long-term immunology patients on homecare registered on the national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23

Blood and Infection
Specialised Immunology and Allergy Services
Specialised Immunology (All Ages)

B09/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
PID05a	Proportion of patients with infusions recorded on the national database within 90 days of treatment taking place / product being issued	Of those patients in the denominator, the number with infusions recorded on the national database within 90 days of treatment taking place / product being issued	The total number of long-term immunology patients registered on the national database	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
PID15a	Proportion of long-term patients who receive an annual review, Immunology only, Exclude private patients	Of those patients in the denominator, the number of patients who have an annual review documented on the Ig national database	The total number of long-term immunology patients registered on the Ig national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
PID16	Proportion of long-term patients who receive a dose review	Of those patients in the denominator, the number who receive a dose review	The total number of eligible long-term patients registered with infusions who are recorded on the national database in the reporting period	Quarter	Quarterly	MDSAS	MDSAS		Immunology only Exclude private patients	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23